GILEAD – Life Cycle Management for HIV and HCV Pipeline = Upside

Date: 2015-07

3Q12 earnings (Table 1) and revised upward revenue guidance validates Gilead’s (GILD) dominance in the HIV space. With the successful launch of Complera/Eviplera (truvada+edurant, 3Q12 net sales of $99m), Stribild (L in US, R in EU, truvada+ cobicistat+elvitegravir) and expected approval of Elvitebravir (R, Integrase inhibitor, 1H13), GILD is set to lead the HIV arena beyond 2018. In the next three years, GILD should be able to repeat the feat in HCV too! For more detail, please read our report released on 1st Nov., 2012, titled, “Life Cycle Management for HIV and HCV Pipeline = Upside”.


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample